Business
Adial Pharmaceuticals Announces Positive In-Vivo Non-clinical Data with Purnovate’s PNV-6005 as a Potential Treatment for Ulcerative Colitis
PNV-6005 significantly reduced both weight loss and colon damage in ulcerative colitis animal model CHARLOTTESVILLE, Va., Sept. 06, 2022 (GLOBE NEWSWIRE) --
About this update from Adial Pharmaceuticals, Inc
[{"type":"text","content":"PNV-6005 significantly reduced both weight loss and colon damage in ulcerative colitis animal model\nCHARLOTTESVILLE, Va., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), today announced that Purnovate, Inc., a subsidiary of Adial focused on developing novel molecules targeting the adenosine receptors for the treatment of major unmet medical needs, achieved positive in-vivo data from its study with mice treated with Purnovate’s PNV-6005 as a potential treatment for inflammatory bowel diseases. PNV-6005 is a selective adenosine 2A receptor agonist designed to have anti-inflammatory properties and protective effects against colitis and other inflammatory bowel diseases (IBD). In the study, PNV-6005 demonstrated statistically significant effect against both primary study endpoints, which are pre-clinical endpoints expected to indicate potential efficacy against ulcerative colitis in humans. Specially, PNV-6005 (i) significantly prevented weight loss as compared to the control group (greater than 50% inhibition of weight loss) and (ii) significantly prevented colon damage as evidenced by reduction of shortening of colon lengths in the PNV-6005 treated group (almost total prevention), as well as a decrease in inflammation as assessed histologically. The study was conducted by Dr. Peter Ernst, DVM, PhD, Professor of Pathology at the University of California San Diego (UC San Diego), an expert in the fields of immunology, inflammation and infectious diseases. A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/1664150a-b1eb-4bc6-874a-e7462f47b19d Study Design The study utilized a DSS- induced colitis model, which is widely used because of its simplicity and similarities with human ulcerative colitisPNV-6005 was administered intraperitoneally twice a day at 6µg/kg dose for 7 daysDSS was administrated at 4% concentration via drinking waterThe study included four groups of 5 mice: (i) one group with normal drinking water; (ii) one group with DSS 4% volume concentration in drinking water; and (iii) two treated groups receiving PNV6005 intraperitoneal injections The positive results follow a recent research collaboration agreement between Purnovate and UC San Diego, a leading education and research university, to evaluate ...